The biotech Inovio said early Friday that the U.S. government had decided to pull funding for a Phase 3 trial of the company’s experimental Covid-19 vaccine, given the “broad availability” of Covid-19 vaccines in the U.S.

Inovio (ticker: INO) said it now plans to run a Phase 3 trial largely outside of the U.S. That would likely impact its ability to get the vaccine approved by the Food and Drug Administration.


Source link